Abstract: Naturally occurring lecithins and/or oleic acid stimulate the growth and lactic acid producing activity of Lactobacillus and Bifidobacterium species of probiotic bacteria, and replace polysorbate 80 for those products. They can be used in naturally occurring form, or where they are to be combined with probiotics in a carrier, or they can be treated to yield a stable powdered form of these naturally oily compounds. They can be sold as combined prebiotic/probiotic formulations in the same carrier, or sold as separate dietary supplements, e.g., in capsule or tablet form, to be used with the probiotic formulation as desired.

Abstract: Ferulate esterase producing bacterial strains or functional mutants thereof and methods of using ferulate esterase producing bacterial strains as forage additives are disclosed.

Abstract: The present invention provides a composition comprising prebiotic and probiotic components and is used to reduce elevated levels of nitrogenous waste products and to promote a healthy bowel microenvironment.

Abstract: Disclosed are methods directed to the cosmetic use of an effective amount of at least one probiotic microorganism especially from the genus Lactobacillus sp. and/or Bifidobacterium sp., of a fraction thereof and/or of a metabolite thereof, as an active agent for limiting, preventing or treating skin irritation and/or irritative skin disorders.

Abstract: A stable, pellet-frozen lactic acid bacteria (LAB) culture comprises at least one additive compound in a commercial relevant package. The pellet-frozen culture has at least 50 g frozen material and a content of viable bacteria of at least 109 colony forming units per gram of frozen material. The individual pellets of the frozen culture do not stick together and remain as individual pellets, when stored at about ?46° C., for at least 7 to 14 days.

Abstract: The present invention relates to compositions for the oral and vaginal administration of human Lactobacilli and uses thereof for physiologic restoration of the vaginal flora, physiologic maintenance of Lactobacillus flora in pathologic deficiency to produce Lactobacilli, treatment of asymptomatic bacterial vaginosis and prevention of preterm delivery caused through bacterial vaginosis.

Abstract: The present invention relates to specific Lactobacillus strains with an anti-oxidant effect.

Abstract: The present invention provides an intestinal tract protective agent comprising a polyphosphoric acid or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The present invention relates to methods for a long-term and sustained release of flavonoids, in particular rhamnose-containing flavonoids, and for prolonging the uptake of said flavonoids in the gastro-intestinal tract. It further relates to compositions comprising said flavonoid and ?-rhamnosidase. It also encompasses compositions comprising hesperidin and hesperetin-7-glucoside.

Abstract: The present invention relates to an isolated Lactobacillus paracasei bacterium, deposited as NRRL B-50314, that secretes a bacteriocin. More specifically, the bacteriocin has antibacterial activity against a range of Gram-positive bacteria, including but not limited to Listeria monocytogenes, Staphylococcus aureus, Enterococcus faecalis, and other Lactobacillus species. Additionally, the bacteriocin has antibacterial activity against methicillin resistant Staphylococcus aureus.

Abstract: The present invention relates to novel strains of lactic acid bacteria, Lactobacillus plantarum subsp. plantarum PM-A0087 deposited as NRRL accession number B-50523, Bifidobacterium longum PM-A0101 deposited as NRRL accession number B-50525, and Bifidobacterium bifidum PM-A0218 deposited as NRRL accession number B-50524.

Abstract: A method is provided of selecting specific probiotic lactic acid bacteria producing histamine and the use of such strains for beneficial effects for mammals. The method includes selecting a lactic acid bacterial strain for use in the local production of histamine in a mammal, and further comprises screening bacteria for the presence of an. active histidine operon and selecting a strain which has an active histidine operon and is capable of producing histamine. Preferably said strain is selected for its ability to produce histamine at a level of greater than 250 pg/ml. The present invention further provides products comprising the strains obtainable by the selection methods of the invention for use in the local production, of histamine in a mammal, in particular for use in the treatment or prophylaxis of inflammatory conditions.

Abstract: Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found.

Abstract: The present invention relates to a novel wild-type Lactococcus lactis subsp. cremoris bacteria strain with increased vitamin K2 production and mutants and variants thereof and methods for preparation of a fermented food or feed product enriched in vitamin K2 and a vitamin K enriched edible product for amelioration and/or prevention of vitamin K deficiency. The present invention also relates to the fermented food or feed product and the edible product obtainable by the methods herein and to the wild-type Lactococcus lactis subsp. cremoris bacteria strain for use in treatment and/or prevention of vitamin K deficiency in a mammal, such as a human.

Abstract: The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to support weight management and to treat or prevent obesity. One embodiment of the present invention relates to the use of Lactobacillus helveticus CNCM I-4095 for the preparation of a composition to support weight management, promote weight loss and/or to treat obesity.

Abstract: Naturally occurring lecithins and/or oleic acid stimulate the growth and lactic acid producing activity of Lactobacillus and Bifidobacterium species of probiotic bacteria, and replace polysorbate 80 for those products. They can be used in naturally occurring form, or where they are to be combined with probiotics in a carrier, or they can be treated to yield a stable powdered form of these naturally oily compounds. They can be sold as combined prebiotic/probiotic formulations in the same carrier, or sold as separate dietary supplements, e.g., in capsule or tablet form, to be used with the probiotic formulation as desired.

Abstract: The present invention is directed toward protecting the cosmetic use of at least an effective amount of a lysate of at least one microorganism of the genus Bifidobacterium species, or a fraction thereof, for preventing and/or treating body odor.

Abstract: A method is described to treat diarrhea, vaginal yeast infections, constipation, heartburn, bloating, indigestion, flatulence or poor nutrient absorption, by administering a formulation of naturally occurring lecithins and/or oleic acid that stimulate the growth and lactic acid producing activity of Lactobacillus and Bifidobacterium species of probiotic bacteria, and replace polysorbate 80 for those products, and a formulation of Lactobacillus and Bifidobacterium species of probiotic bacteria. The formulations are in can a stable powdered form.

Abstract: New strains of Lactobacillus that have been selected for their capability of improved reduction the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with better binding to the oral mucins and dental plaque, thereby preventing, reducing or treating dental caries, and products derived from said strains, including agents for treatment or prophylaxis of caries for administration to humans.

Abstract: The present invention discloses strains of Lactobacillus and Streptococcus which have a capacity to degrade gliadin peptides involved in coeliac disease and which peptide degrading activity is stable under low pH and in the presence of mammalian digestive enzymes. These strains are suitable in a product for use in prevention and/or treatment of celiac disease.

Abstract: Isolated strains of Lactobacillus plantarum are described that have anti-fungal activity against fungal spore suspensions, and specifically anti-fungal activity in fruit juices and fermented dairy products. The two species have also been found to have a high degree of heat tolerance and osmotolerance, and to have a high freeze-drying survival rate.

Abstract: The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to treat obesity. One embedment of the present invention relates to the use of Lactobacillus rhamnosus CGMCC 1.3724 and/or Lactobacillus rhamnosus NCC 4007 for the preparation of a composition to support weight management, promote weight loss and/or to treat obesity.

Abstract: Provide a visceral fat reducing agent for reducing the diseases and conditions associated with the metabolic syndrome which represents a condition where various risk factors such as those for hypertension, hyperlipemia, glucose tolerance dysfunction, etc., have accumulated, or simply reducing an accumulation of visceral fat, wherein the effective ingredient of said visceral fat reducing agent includes fungus bodies of lactic bacteria, especially lactic bacteria belonging to the Lactobacillus sp. and Lactococcus sp. and/or cultures thereof, while also providing a beverage, food or feed containing said visceral fat reducing agent.

Abstract: The present invention relates generally to the field of cosmetic and/or food supplement. More specifically, the present invention aims to provide the use of at least an ingredient containing chicoric acid and/or derivatives and a micro-organism and/or an enzyme capable of hydrolyzing chicoric acid and/or derivatives thereof to generate tartaric and/or caffeic acid, for improving skin tone and preventing and/or treating hyper-pigmentation of skin and/or skin color imperfections such as age-spots and other skin disorders characterized by abnormal pigments. Also, the present invention aims at providing a skin lightening agent.

Abstract: An herbal vaginal composition for treating vaginal infections while maintaining the natural vaginal flora, herbal ingredients comprising: coconut oil as the base ingredient, shea butter, neem oil, lavender oil, vitamin E, lactobacillus, green tea, tea tree, ylang ylang, sweet orange, myrrh, frankincense, nirvanas base, and clove oil.

Abstract: The present invention relates to an aquatic animal feed product comprising metabolite derived from probiotic LAB. Hence, such a feed product is highly suitable for use as a feed product for an aquatic animal.

Abstract: The present disclosure is directed to compositions comprising Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483 or a mutant or variant thereof. This composition is useful in the treatment of gastrointestinal diseases or conditions such as Inflammatory Bowel Disease, Irritable Bowel Syndrome, or abdominal distension and bloating.

Abstract: The present disclosure relates to nutritional compositions comprising a prebiotic component for inhibiting adherence of pathogens in the gastrointestinal tract of a subject and to the prebiotic component, which comprises galactooligosaccharide, polydextrose or any mixture thereof. The nutritional compositions of the present disclosure comprise a fat or lipid source, a protein source, and a carbohydrate source comprising an effective amount of the prebiotic component.

Abstract: An isolated Lactobacillus paracasei strain GMNL-133 is disclosed, which was deposited in the China Center for Type Culture Collection (CCTCC) under the accession number of CCTCC M 2011331 is disclosed. The isolated Lactobacillus paracasei strain GMNL-133 is used for preparing a composition for use in the treatment of atopic dermatitis or other allergic diseases in an effective amount. And a composition for use in the treatment of atopic dermatitis or other allergic diseases comprises an effective amount of the Lactobacillus paracasei strain GMNL-133 is also disclosed.

Abstract: Disclosed are compounds of formula (I): or a pharmaceutically acceptable N-oxide, salt, hydrate, solvate, complex, bioisostere, metabolite or prodrug thereof, which are of use in the treatment of infection with, and diseases caused by, Clostridium difficile.

Abstract: Lactobacillus strains that have a genetic Profile I based on Apa I, Not I, and Xba I digests are provided. Preferably, the strains decrease level of at least one of coliforms and E. coli within the gastrointestinal tract of an animal. A direct-fed microbial that includes the strain is additionally provided. A method of feeding an animal the strain and a method of forming a direct fed microbial that includes the strain is also provided.

Abstract: The present invention provides a method for inhibiting blood phosphorus level elevation, including administering to a patient in need thereof a composition comprising a lactic acid bacterium as an active ingredient. The method may further include encapsulating the composition comprising a lactic acid bacterium in a capsule. The inhibitor for blood phosphorus level elevation of the present invention is highly safe, is readily administrable, and can sufficiently inhibit a blood phosphorus level elevation.

Abstract: The invention relates to compositions for treating parasitic worm infections in a mammal. The composition includes an amount of intracellular components of lysed, beneficial, soil-inhabiting yeast cells sufficient to treat parasitic worm infections in a mammal; and/or an amount of whole or lysed soil-inhabiting bacteria cells, wherein the amount is sufficient to treat parasitic worm infections in a mammal, and optionally a pharmaceutically suitable carrier.

Abstract: Provided is an isolated Lactobacillus plantarum CMU995, which was deposited at the Food Industry Research and Development Institute in Taiwan with the accession number BCRC 910472 and in the German Collection of Microorganisms and Cell Cultures (DSMZ) under accession number DSM 23780. Also provided are a composition comprising Lactobacillus plantarum CMU995 and a method for inhibiting pathogens, protecting the gastrointestinal tract, and/or protecting the urinary tract in a mammal comprising administrating an effective amount of Lactobacillus plantarum CMU995 to the mammal.

Abstract: A probiotic composition, delivery device, method of forming, and a method for delivery are disclosed. The composition may be in the form of a spray, mist, film, or the like suitable for use with any pre-formulated pet food product, whether in solid or liquid form, and further to the use of the spray directly on the coat or skin of an animal. The probiotic spray may also be applied directly into a cavity of the animal, for example into its mouth or nasal passages. The probiotic composition provides multiple strains or species of viable bacteria that provide health benefits when ingested, and is shown herein primarily for consumption by or use on/in animals, though the invention is not limited in any way to use strictly for animal intake, but may also be suitably used for human ingestion.

Abstract: Ferulate esterase producing bacterial strains or functional mutants thereof and methods of using ferulate esterase producing bacterial strains as forage additives are disclosed.

Abstract: The invention features a food product containing a probiotic and ?-glucan isolated from a natural source, methods of treating a disease or disorder by administering the food product, and a package containing separated components of the food product.

Abstract: A preparation for use in the treatment of clostridium difficile or salmonella infection comprising a mixture of galacto-oligosaccharide and matter from cranberry, and uses thereof.

Abstract: The present invention relates to shelf-stable liquid products, for example diary products, comprising micro-organisms, especially probiotics. The micro-organisms are able to survive for several months at room temperature basically due to their inability to metabolise nutrients contained in the liquid product. The invention further relates to a method for manufacturing the liquid product according to the invention.

Abstract: The present invention pertains to a composition for inducing a pattern of gut barrier maturation similar to that observed with breast-feeding and able to improve gut barrier maturation, e.g. during neonatal stress. In particular, the present invention relates to an infant formula containing a combination of specific ingredients designed to provide a synergistic effect all along gastrointestinal tract and barrier function.

Abstract: The present invention provides lactic acid bacteria which are suitable for use for dietary products and pharmaceuticals, and which can suppress the increase of blood uric acid level. Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2922, were found.

Abstract: An immunomodulatory isolated Lactobacillus strain is disclosed. The isolated Lactobacillus strain (accession No. CCTCC M 2011279) is purified from plant fermentation products. The isolated Lactobacillus strain, whatever itself or the composition including the same, can specifically enhance the amount of nitric oxide (NO), tumor necrosis factor-? (TNF-?) and interleukin-6 (IL-6), and also specifically enhance phagocytosis of macrophages, thereby enhancing the immunomodulatory ability of a host. Moreover, the isolated Lactobacillus strain of the present invention itself, or a food or its ingredient, a food supplement or a medical composition including the isolated Lactobacillus strain, can enhance the immunomodulatory ability by oral administration.

Abstract: The present disclosure defines a method for identifying and/or treating risk and/or occurrence of cardiac defect. As is shown herein, microbiomes are reproducibly and detectably associated with cardiac defect risk factors and changes to the microbiome can directly alter cardiac defect risk. The present disclosure demonstrates that microbial signatures can be used to characterize components of microbiomes that associate with altered risk or occurrence of cardiac defects and to identify treatments to reduce risk or severity of cardiac defects.

Abstract: It is to provide a composition derived from lactic acid bacteria having an anti-allergic effect (an effect of suppressing allergic symptoms such as hay fever) synergistically, and a food product, pet food, etc. containing the composition. It is to prepare a composition having an anti-allergic action, containing Lactobacillus crispatus KT-11 strain, KT-23 strain, or KT-25 strain bacterial cells and viable bacteria, dead bacteria, or a processed product of bacterial cells of other lactic acid bacteria belonging to the genus Lactobacillus, genus Bifidobacterium, genus Leuconostoc, genus Enterococcus, genus Pediococcus, etc. at a biomass-converted ratio of 99:1 to 50:50, preferably 99:1 to 75:25.

Abstract: The invention relates to an infant formula comprising a source of protein in an amount of not more than 2.0 g/100 kcal, a source of lipids, a source of carbohydrate and a probiotic wherein the probiotic is present in an amount equivalent to between 102 and 105 cfu/g of dry formula. The invention further extends to the use of such an infant formula to modulate the immune system of a neonatal infant to promote the development in the first few weeks of the life of the infant of a beneficial intestinal microbiota comparable with that found in breast fed babies as well as to promote the maturation of the immune system of a neonatal infant in the first few weeks of life.

Abstract: The present invention pertains to the use of probiotics for the preparation of a carrier for balancing the skin's immune function. In particular, the present invention pertains to the use of probiotic micro-organisms for balancing the skin's immune function under stress conditions, such as a exposure to ultraviolet radiation, specifically for enhancing the skin's immune activity and reducing the tendency to develop allergic reactions under such conditions.

Abstract: An isolated Lactobacillus paracasei strain LT12 and its genetically-engineered variant that possesses immune regulating activity and uses thereof for regulating immune responses and treating allergy.

Abstract: The present invention generally relates to the field of preventing and/or treating inflammatory and infectious disorders, in particular by boosting the endogenous antimicrobial defences. One embodiment of the present invention is the use of non-replicating L. johnsonii La1 NCC533 (deposit number CNCM I-1225) for use in the treatment or prevention of disorders related to the immune system including infections.

Abstract: A method is provided of selecting specific probiotic lactic acid bacteria producing histamine and the use of such strains for beneficial effects for mammals. The method includes selecting a lactic acid bacterial strain for use in the local production of histamine in a mammal, and further comprises screening bacteria for the presence of an active histidine operon and selecting a strain which has an active histidine operon and is capable of producing histamine. Preferably said strain is selected for its ability to produce histamine at a level of greater than 250 pg/ml. The present invention further provides products comprising the strains obtainable by the selection methods of the invention for use in the local production of histamine in a mammal, in particular for use in the treatment or prophylaxis of inflammatory conditions.

Abstract: A method is provided for preparing a raw material for functional foods from vernalized, pre-germinated barley or wheat seeds, plumules cultured the vernalized, pre-germinated barley or wheat seeds, or a material resulting from the fermentation of the vernalized, pre-germinated barley or wheat seeds with lactic acid bacteria.